The biopharma sector has experienced a significant resurgence in dealmaking activity during 2026, with transaction volumes and values reaching levels not seen since 2020. According to PwC’s midyear outlook for pharmaceutical and life sciences deals, more than $65 billion in deal value was recorded during the first quarter alone, prompting the firm to conclude that the “biopharma ecosystem is back to full health.”
A total of 16 mergers and acquisitions valued at $1 billion or more were announced during the first quarter. Activity has been concentrated around differentiated scientific assets, expansion opportunities in GLP-1 therapies, and emerging modalities such as RNA-based medicines, antibody-drug conjugates (ADCs), and gene-editing technologies.
The momentum has continued into the second quarter, highlighted by two of the largest healthcare transactions announced so far this year: Sun Pharma’s $11.75 billion acquisition of Organon and GSK’s $10.6 billion purchase of Nuvalent.
PwC noted that pharmaceutical companies are increasingly motivated by the need to address substantial revenue exposure from upcoming patent expirations. The report stated, “Strategic dealmaking urgency has intensified.”
The firm further observed that large pharmaceutical companies are actively deploying capital after several years of relatively modest transaction activity. “After sitting out the first half of the decade and only making smaller deals, large pharmaceutical players are digging into their deep pockets to offset the estimated $300 billion of branded pharma revenue exposed to loss of exclusivity this decade.”
Despite ongoing industry challenges—including tariffs, drug-pricing policies, and geopolitical trade uncertainties—M&A activity has remained resilient. However, transaction structures are evolving, with acquirers placing greater emphasis on contingent value rights, milestone-based payments, and assets approaching key clinical or commercial milestones.
Looking ahead, PwC expects both deal volume and value to remain elevated. The firm cites continued demand from large pharmaceutical companies alongside improving conditions for biotechnology companies as the IPO market gradually reopens.
Roel van den Akker, PwC’s U.S. pharmaceutical & life sciences deals leader, said, “Biopharma M&A has entered a new phase driven less by scale and more by precision science. We expect M&A to remain strong through year-end as large caps close LOE gaps with high-conviction science across cardiometabolic, CNS, immunology and oncology.”
PwC concluded that capital remains readily available, while differentiated assets with near-term commercial potential remain the sector’s
